Indeed, both anti-CD47 monotherapy and the combined treatment of anti-CD47 with PARPi facilitate macrophage-mediated in-vitro phagocytosis, boost STING signaling, and eliminate tumor growth in BRCA-deficient ovarian cancer models [165]. This evidence concerns the gene CD47 and ovarian cancer.